Format

Send to

Choose Destination
See comment in PubMed Commons below
MAbs. 2012 Mar-Apr;4(2):134-52. doi: 10.4161/mabs.4.2.19426. Epub 2012 Mar 1.

7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.

Author information

1
Merrimack Pharmaceuticals Inc.; Cambridge, MA USA.
2
Landes Bioscience; Austin, TX USA.
3
Centre d'Immunologie Pierre Fabre; Saint-Julien en Genevois, France.

Abstract

The 7th European Antibody Congress (EAC), organized by Terrapin Ltd., was again held in Geneva, Switzerland, following on the tradition established with the 4th EAC. The 2011 version of the EAC was attended by nearly 250 delegates who learned of the latest advances and trends in the global development of antibody-based therapeutics. The first day focused on advances in understanding structure-function relationships, choosing the best format, glycoengineering biobetter antibodies, improving the efficacy and drugability of mAbs and epitope mapping. On the second day, the discovery of novel targets for mAb therapy, clinical pipeline updates, use of antibody combinations to address resistance, generation and identification of mAbs against new targets and biosimilar mAb development were discussed. Antibody-drug conjugates, domain antibodies and new scaffolds and bispecific antibodies were the topics of the third day. In total, nearly 50 speakers provided updates of programs related to antibody research and development on-going in the academic, government and commercial sectors.

KEYWORDS:

antibody-drug conjugates; biosimilar antibodies; bispecific antibodies; protein scaffolds; therapeutic antibodies

PMID:
22453093
PMCID:
PMC3361652
DOI:
10.4161/mabs.4.2.19426
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center